1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Epiomic Epidemiology Series: Chronic Kidney Disease Forecast in 19 Major Markets 2016-2026

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Chronic Kidney Disease (CKD) in 19 Major Markets

Chronic kidney disease (CKD), also known as chronic renal disease, is characterised by progressive loss of kidney function over time. CKD is defined as persisting kidney damage or a glomerular filtration rate (GFR) of <60 mL/min/1.73 m2 for - 3 months. This damage refers to any renal pathology that has the potential to cause a reduction in renal functional capacity, such as GFR.

This report provides the current prevalent population for CKD across 19 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Turkey, Mexico, Australia, Canada, Norway, Ireland, Netherlands, Poland, South Korea and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of CKD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for CKD include:

• Hypertension
• Diabetes
• Chronic heart failure
• Anaemia
• Hyperphosphatemia
• Increased risk of infection
• End stage renal disease
• Acute kidney injury

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global CKD’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of CKD and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on CKD’s prevalent population.
• Identify sub-populations within CKD which require treatment.
• Gain an understanding of the specific markets that have the largest number of CKD patients.

Table Of Contents

Epiomic Epidemiology Series: Chronic Kidney Disease Forecast in 19 Major Markets 2016-2026
Table of Contents
- List of Tables and Figures
- Introduction
- Cause of the Disease
- Risk Factors and Prevention
- Diagnosis of the Disease
- Variation by Geography/Ethnicity
- Disease Prognosis and Clinical Course
- Key Co-morbid Conditions/Features Associated with the Disease
- Methodology for Quantification of Patient Numbers
o Additional data available on request
- Top-Line Prevalence for Chronic Kidney Disease
- Features of Chronic Kidney Disease Patients
o CKD by Stage of Disease
o ESRD Therapy
o Associated Conditions of CKD Patients
o Associated Conditions of ESRD Patients
- Abbreviations used in the Report
- Other Black Swan Analysis Publications
- Black Swan Analysis Online Patient-Based Databases
- Patient-Based Offering
- Online Pricing Data and Platforms
- References
- Appendix

List of Tables

- National Kidney Foundation's CKD KDOQI Clinical Practice Guidelines for CKD
- Prevalence of CKD, total (000s)
- Prevalence of CKD, males (000s)
- Prevalence of CKD, females (000s)
- Stage of CKD patients, total (000s)
- Renal replacement therapy in Stage V (ESRD) CKD patients, total (000s)
- Prevalence of diabetes in CKD, total (000s)
- Prevalence of elevated CRP in CKD, total (000s)
- Prevalence of myocardial infarction in CKD, total (000s)
- Prevalence of diabetes in ESRD patients, total (000s)
- Prevalence of hypertension in ESRD patients, total (000s)
- Prevalence of glomerulonephritis in ESRD patients, total (000s)
- Abbreviations and Acronyms used in the report
- USA Prevalence of CKD by 5-yr age cohort, males (000s)
- USA Prevalence of CKD by 5-yr age cohort, females (000s)
- France Prevalence of CKD by 5-yr age cohort, males (000s)
- France Prevalence of CKD by 5-yr age cohort, females (000s)
- Germany Prevalence of CKD by 5-yr age cohort, males (000s)
- Germany Prevalence of CKD by 5-yr age cohort, females (000s)
- Italy Prevalence of CKD by 5-yr age cohort, males (000s)
- Italy Prevalence of CKD by 5-yr age cohort, females (000s)
- Spain Prevalence of CKD by 5-yr age cohort, males (000s)
- Spain Prevalence of CKD by 5-yr age cohort, females (000s)
- United Kingdom Prevalence of CKD by 5-yr age cohort, males (000s)
- United Kingdom Prevalence of CKD by 5-yr age cohort, females (000s)
- Brazil Prevalence of CKD by 5-yr age cohort, males (000s)
- Brazil Prevalence of CKD by 5-yr age cohort, females (000s)
- Japan Prevalence of CKD by 5-yr age cohort, males (000s)
- Japan Prevalence of CKD by 5-yr age cohort, females (000s)
- India Prevalence of CKD by 5-yr age cohort, males (000s)
- India Prevalence of CKD by 5-yr age cohort, females (000s)
- Turkey Prevalence of CKD by 5-yr age cohort, males (000s)
- Turkey Prevalence of CKD by 5-yr age cohort, females (000s)
- Mexico Prevalence of CKD by 5-yr age cohort, males (000s)
- Mexico Prevalence of CKD by 5-yr age cohort, females (000s)
- Australia Prevalence of CKD by 5-yr age cohort, males (000s)
- Australia Prevalence of CKD by 5-yr age cohort, females (000s)
- Canada Prevalence of CKD by 5-yr age cohort, males (000s)
- Canada Prevalence of CKD by 5-yr age cohort, females (000s)
- Norway Prevalence of CKD by 5-yr age cohort, males (000s)
- Norway Prevalence of CKD by 5-yr age cohort, females (000s)
- Ireland Prevalence of CKD by 5-yr age cohort, males (000s)
- Ireland Prevalence of CKD by 5-yr age cohort, females (000s)
- Netherlands Prevalence of CKD by 5-yr age cohort, males (000s)
- Netherlands Prevalence of CKD by 5-yr age cohort, females (000s)
- Poland Prevalence of CKD by 5-yr age cohort, males (000s)
- Poland Prevalence of CKD by 5-yr age cohort, females (000s)
- South Korea Prevalence of CKD by 5-yr age cohort, males (000s)
- South Korea Prevalence of CKD by 5-yr age cohort, females (000s)
- China Prevalence of CKD by 5-yr age cohort, males (000s)
- China Prevalence of CKD by 5-yr age cohort, females (000s)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Bovine Respiratory Disease Treatment Market: Overview Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.